Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
Open Access
- 12 November 2021
- journal article
- review article
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-11
Abstract
Background: Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed and refractory patients with multiple myeloma (MM). However, there is limited evidence on treatment patterns and effectiveness of daratumumab in the real-world setting, particularly in first line (1 L). This study aimed to describe real-world treatment patterns and clinical outcomes among patients initiating daratumumab across different lines of therapy. Methods: A retrospective chart review of adult patients with MM initiating daratumumab between November 2015 and March 2021 was conducted at two clinical sites in the United States. De-identified patient-level data were abstracted in an electronic case report form. Patient characteristics and treatment patterns were described. Clinical outcomes including overall response rate (ORR), progression-free survival, and time to next line of therapy were reported using descriptive statistics and stratified by line of therapy (1 L, second line [2 L] or third line or later [3 L+]). A sub-group analysis evaluated treatment patterns and ORR among patients re-treated with daratumumab. Results: A total of 299 patients were included in the study (mean age: 68 years; 55% male). Among them, 26 were 1 L patients, 66 were 2 L patients, and 207 were 3 L+ patients; 110 patients (36.8%) received a stem cell transplant prior to daratumumab initiation. The mean duration of follow-up was 10 months among 1 L patients and 19 months among 2 L and 3 L+ patients. Patients who initiated daratumumab in 1 L had a 100% ORR, while those initiating in 2 L and 3 L+ had an ORR of 78.8 and 65.2%, respectively. Among re-treated patients, ORR was 66.7% during the first treatment segment, and 52.9% during the second treatment segment. Kaplan-Meier rates of progression-free survival at 12 months were 89.9, 75.2, and 53.1% among patients who initiated daratumumab in 1 L, 2 L, and 3 L+, respectively. Kaplan-Meier rates of time to next line of therapy at 12 months were 94.1, 73.4, and 50.0% among patients who initiated daratumumab in 1 L, 2 L, and 3 L+, respectively. Conclusions: These findings suggest that daratumumab-based regimens are an effective treatment option across all lines of therapy, with highest response rate in 1 L.Keywords
This publication has 25 references indexed in Scilit:
- Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patientsCurrent Medical Research and Opinion, 2018
- Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaBlood, 2017
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupBlood, 2016
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialThe Lancet, 2016
- Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaNew England Journal of Medicine, 2015
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupJournal of Clinical Oncology, 2015
- Multiple myelomaBMJ, 2013